Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T19:12:41.143Z.
Calculation as of: 2026-10-06T19:12:41.143Z.
Quote observation: 2026-10-06T19:10:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 42f8c92a8b380efb6649096d6ff86922fd6625672ce9883573e20b441a6c115b
PEG RATIO
N/A
MiMedx Group, Inc.
Market Cap
$661.02M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| MiMedx Group, Inc. (MDXG) | $661.02M | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $663.91M | N/A |
| Starling Oncology, Inc. (STLN)vs › | $657.84M | N/A |
| Helus Pharma Inc. (HELP)vs › | $664.49M | N/A |
| Prime Medicine, Inc. (PRME)vs › | $654.74M | N/A |
| Annexon, Inc. (ANNX)vs › | $668.89M | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $679.58M | N/A |
| Verastem, Inc. (VSTM)vs › | $687.02M | N/A |
| Wave Life Sciences Ltd. (WVE)vs › | $687.70M | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $633.57M | N/A |
PEG Ratio
N/A
P/E Ratio
113.4
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
